Boston, MA 05/08/2014 (wallstreetpr) – The aggregate principal prices of three unsecured senior notes were announced by Celgene Corporation (NASDAQ:CELG) today. The company has priced these at $2.5 billion. Of these three notes in question, $500 million will mature in 2019 bearing an annual interest of 2.25%. Another worth $1000 million will mature in 2024 and it bears an interest rate of 3.625%. Lastly the third of the trio is worth $1000 million and is supposed to mature in 2044 and will have an interest rate of 4.625%. These three bills are priced in a path as to lead 2.303%, 3.666% and 4.647% respectively.
Proceeds to be poured into
It is expected that Celgene Corporation (NASDAQ:CELG) will use the net yield from such an offering for general corporate uses. General corporate purposes are likely to include further development of the company’s clinical as well as pre-clinical programs, general activities, capital expenditures, meeting the need of working capital, repurchases of their own common stock and also repayment of their outstanding commercial paper. This offering is likely to close on May 15 of this year.
Book runners for this sale
The present book runners for this sale are Merill Lynch, Pierce, Fenner & Smith, Inc., Goldman, Sachs & Co., Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC. These companies are acting as joint book running managers for the deal.
A transcript of the preliminary prospectus supplement along with the base prospectus can be obtained by interested parties at any of the joint book running managers.
An electronic copy of the base and supplement prospectus can also be received at no cost from the internet site of the Securities and Exchange Commission.
It has stated that the oblation of the notes will only be reached by means of the prospectus supplement and the accompanying base prospectus.
Celgene Corporation (NASDAQ:CELG), which is headquartered in Summit, New Jersey, is a biopharmaceutical company with presence all over the world. The company primarily engages itself in discovering, developing and marketing of therapies for cancer and inflammatory diseases. These therapies are generally taken out through gene and protein regulation.
